The term cancer and the heart is readily associated with the cardiotoxicity of antineoplastic agents, such as anthracyclines or receptor tyrosine kinase inhibitors. This Viewpoint offers a different perspective, drawing attention to the consequences of metabolic dysregulation in cancers for energy substrate metabolism and contractile function of the heart and to common cellular strategies present in cancers and in the failing heart.
Keywords: fetal heart; heart; heart failure; isocitrate dehydrogenase; metabolism; neoplasms; pyruvate kinase.